Wren Therapeutics is commercialising Cambridge and Lund research into therapies for protein misfolding diseases, which include Alzheimer's and motor neurone disease.

Wren Therapeutics, a UK-based small molecule and antibody treatment developer spun out of University of Cambridge and Lund University, closed a £18m ($23.3m) series A round today led by hedge fund Baupost Group.
Venture capital firm LifeForce Ventures and multiple unnamed private investors also took part in the round.
Founded in 2016, Wren Therapeutics is working on small molecule and antibody therapies for so-called protein misfolding diseases, whereby certain proteins in the body have become structurally abnormal and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?